Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Amgen Inc.
  6. News
  7. Summary
    AMGN   US0311621009

AMGEN INC.

(AMGN)
  Report
Delayed Nasdaq  -  04:00 2022-09-27 pm EDT
225.99 USD   -0.39%
09/27AstraZeneca Says Bronchial Asthma Treatment Approved in Japan
MT
09/22US Stocks End Lower Thursday Despite Healthcare Gains
MT
09/22US Stocks End Lower Thursday Despite Surge in Healthcare Shares
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

SENATE FINANCE COMMITTEE CHAIRMAN WYDEN SENDS AMGEN LETTER INQUI…

08/11/2022 | 01:33pm EDT

SENATE FINANCE COMMITTEE CHAIRMAN WYDEN SENDS AMGEN LETTER INQUIRING ABOUT TAX PRACTICES


© Reuters 2022
All news about AMGEN INC.
09/27AstraZeneca Says Bronchial Asthma Treatment Approved in Japan
MT
09/22US Stocks End Lower Thursday Despite Healthcare Gains
MT
09/22US Stocks End Lower Thursday Despite Surge in Healthcare Shares
MT
09/21EU approves AstraZeneca-Amgen treatment for severe asthma
RE
09/19Novartis' Biosimilar for Osteoporosis Drug Xgeva Matches Reference Therapy in Safety, E..
MT
09/16Amgen : Is Ready to Meet Growing Demand for Innovative Medicines, Says Bradway in Bloomber..
PU
09/15Consumer group says drugmakers abuse U.S. patent system to keep prices high
RE
09/15Transcript : Amgen Inc. Presents at BofA Securities Global Healthcare Confere..
CI
09/13Asthma Peak Week : What You Need to Know About Indoor Air Pollution
PU
09/13Transcript : Amgen Inc. Presents at Morgan Stanley 20th Annual Global Healthc..
CI
More news
Analyst Recommendations on AMGEN INC.
More recommendations
Financials (USD)
Sales 2022 26 146 M - -
Net income 2022 6 293 M - -
Net Debt 2022 27 027 M - -
P/E ratio 2022 19,2x
Yield 2022 3,43%
Capitalization 121 B 121 B -
EV / Sales 2022 5,66x
EV / Sales 2023 5,38x
Nbr of Employees 24 200
Free-Float 99,8%
Chart AMGEN INC.
Duration : Period :
Amgen Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends AMGEN INC.
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 27
Last Close Price 225,99 $
Average target price 249,81 $
Spread / Average Target 10,5%
EPS Revisions
Managers and Directors
Robert A. Bradway Chairman, President & Chief Executive Officer
Peter H. Griffith Chief Financial Officer & Executive Vice President
David M. Reese Senior VP-Translational Sciences & Oncology
Darryl Sleep Chief Medical Officer & Senior VP-Global Medical
Mike Zahigian Chief Information Officer & Senior Vice President
Sector and Competitors
1st jan.Capi. (M$)
AMGEN INC.0.45%120 889
JOHNSON & JOHNSON-3.58%435 655
ELI LILLY AND COMPANY11.32%292 179
ROCHE HOLDING AG-19.31%253 262
ABBVIE INC.4.29%249 673
PFIZER, INC.-25.33%245 989